Ä¢¹½´«Ã½, the worldÄ¢¹½´«Ã½™s leading provider of products and services for individuals with renal diseases, has again been named to the Top 100 Women-Led Businesses in Massachusetts. The annual list is compiled by The WomenÄ¢¹½´«Ã½™s Edge in partnership with The Boston Globe Magazine. Ä¢¹½´«Ã½ ranked #4 Ä¢¹½´«Ã½“ as it did in 2024.Â
Helen Giza, CEO and Chair of the Management Board, continues to lead the companyÄ¢¹½´«Ã½™s strategic realignment under the FME Reignite strategy, which will guide Ä¢¹½´«Ã½Ä¢¹½´«Ã½™s direction and innovation in kidney care for the coming years. In 2024, Ä¢¹½´«Ã½ received FDA clearance for the 5008Xâ„¢ CAREsystem, enabling hemodiafiltration (HDF) therapy in the United States for the first time. The company continues the rollout of the 5008X in the U.S. for the commercial rollout in 2026. This advancement introduces our patients in the U.S. to a new treatment that has demonstrated promising results in Europe and other regions, including reduced hospitalization rates and lower mortality rates.Â
FME has achieved a global Patient Net Promoter Score of 72, reflecting strong patient trust and satisfaction across care settings. The company is uniquely positioned in the industry as the only dialysis provider with a successful vertically integrated structure that combines services and medtech.Â
The WomenÄ¢¹½´«Ã½™s Edge is a Boston-based nonprofit organization that supports women leaders across industries. This year marks the 25th anniversary of its Top 100 list, which recognizes organizations making a measurable impact on the Massachusetts economy through leadership, innovation, and performance. Rankings are based on revenue, diversity, and other key metrics.Â
The ranked list was revealed at the WomenÄ¢¹½´«Ã½™s Edge awards breakfast on Friday, October 24, and published in the October 26 edition of the Boston GlobeÄ¢¹½´«Ã½™s Women & Power magazine. The full list can be viewed .